Applied Therapeutics Inc (APLT)

$1.00 +0.07 (7.04%)
Market Cap 134.54M
Revenue (ttm) 460,000.00
Net Income (ttm) -105.62M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -22,960.87%
Debt to Equity Ratio 0.00
Volume 9,391,200
Avg Vol 5,070,612
Day's Range N/A - N/A
Shares Out 144.01M
Stochastic %K 63%
Beta 2.07
Analysts Sell
Price Target $3.17

Company Profile

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, an...

Industry: Biotechnology
Sector: Healthcare
Phone: 212 220 9226
Address:
545 Fifth Avenue, Suite 1400, New York, United States
SaudTwits
SaudTwits Oct. 4 at 2:43 PM
$APLT I have bought at $0.94 So, what next?
2 · Reply
nevermind889
nevermind889 Oct. 4 at 12:52 PM
$APLT 5$ PT June 2026 I hope we can get there a lot sooner!
0 · Reply
nevermind889
nevermind889 Oct. 4 at 11:59 AM
$APLT Don't forget they still have partnership with ADVANZ Pharma for the commercialization of AT-007 in Europe. Should all the pieces fall in place, they could receive milestone payment of over 130M and 20% royalty payment in Europe! https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-partnership-advanz-pharma "Advanz Pharma receives exclusive commercial rights in the European Economic Area, Switzerland, and the UK for AT-007 in Galactosemia and SORD Deficiency, with certain rights to future indications for AT-007 in Europe."
0 · Reply
nevermind889
nevermind889 Oct. 4 at 11:42 AM
$APLT My only regret is I had another 90k USD ready to deploy but I chickened out! Plus having 420,690 shares is so meme I just had to roll with it.. we always wish we bought more right?
2 · Reply
DJW009
DJW009 Oct. 3 at 10:52 PM
$APLT Closes at $1.00 on 9.28M shares. Clearly, the shorts no longer have an impact.
1 · Reply
MrStockPops
MrStockPops Oct. 3 at 8:58 PM
$APLT concerning compliance this could jump in a big way …
2 · Reply
wavw
wavw Oct. 3 at 8:06 PM
$APLT higher-highs…don’t miss this one.
0 · Reply
nevermind889
nevermind889 Oct. 3 at 8:03 PM
$APLT Start the count. 1$ close, 10 more consecutive days and we'll be in-the-money! Week of 10/14 thru 10/18 is only 11 days away!
0 · Reply
FyCkD_FuNnY
FyCkD_FuNnY Oct. 3 at 8:01 PM
$APLT eTrade shows Closed at $1.00
0 · Reply
XQuise
XQuise Oct. 3 at 8:00 PM
$APLT 🧠👈🏻
0 · Reply
Latest News on APLT
Applied Therapeutics Provides Update Following Meeting with FDA

Sep 29, 2025, 7:00 AM EDT - 5 days ago

Applied Therapeutics Provides Update Following Meeting with FDA

Applied Therapeutics Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 5:11 PM EDT - 7 weeks ago

Applied Therapeutics Reports Second Quarter 2025 Financial Results

Applied Therapeutics Announces Key Leadership Appointments

Jun 17, 2025, 4:05 PM EDT - 3 months ago

Applied Therapeutics Announces Key Leadership Appointments

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

May 18, 2025, 7:28 AM EDT - 4 months ago

Applied Therapeutics Presents Full 12-Month Clinical Results and New Topline Data from INSPIRE Phase 2/3 Trial of Govorestat in CMT-SORD in Late-Breaking Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Applied Therapeutics Reports First Quarter 2025 Financial Results

May 13, 2025, 5:00 PM EDT - 5 months ago

Applied Therapeutics Reports First Quarter 2025 Financial Results

Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

May 9, 2025, 5:00 PM EDT - 5 months ago

Applied Therapeutics Announces Acceptance of Late-Breaking Abstract for Oral Presentation at the Peripheral Nerve Society 2025 Annual Meeting

Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission

Mar 31, 2025, 7:10 AM EDT - 6 months ago

Applied Therapeutics Files Form 12b-25 with the Securities and Exchange Commission

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

Mar 19, 2025, 7:00 AM EDT - 7 months ago

Applied Therapeutics Appoints Todd F. Baumgartner, MD, MPH as Chief Regulatory Officer

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

Feb 16, 2025, 9:20 AM EST - 8 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

APLT COURT NEWS: Applied Therapeutics has been Sued for Securities Fraud; Contact BFA Law by February 18 if You Lost Money (NASDAQ:APLT)

Feb 16, 2025, 7:18 AM EST - 8 months ago

APLT COURT NEWS: Applied Therapeutics has been Sued for Securities Fraud; Contact BFA Law by February 18 if You Lost Money (NASDAQ:APLT)

APLT Deadline: Rosen Law Firm Urges Applied Therapeutics, Inc. (NASDAQ: APLT) Investors to Contact the Firm for Information About Their Rights

Feb 15, 2025, 2:20 PM EST - 8 months ago

APLT Deadline: Rosen Law Firm Urges Applied Therapeutics, Inc. (NASDAQ: APLT) Investors to Contact the Firm for Information About Their Rights

Shareholders of Applied Therapeutics, Inc. Should Contact The Gross Law Firm Before February 18, 2025 to Discuss Your Rights - APLT

Feb 13, 2025, 5:45 AM EST - 8 months ago

Shareholders of Applied Therapeutics, Inc. Should Contact The Gross Law Firm Before February 18, 2025 to Discuss Your Rights - APLT

APLT SHAREHOLDER NEWS: Applied Therapeutics Investors that Lost Money may have been affected by Fraud - Contact BFA Law by February 18 Deadline

Feb 12, 2025, 3:18 PM EST - 8 months ago

APLT SHAREHOLDER NEWS: Applied Therapeutics Investors that Lost Money may have been affected by Fraud - Contact BFA Law by February 18 Deadline

APLT DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Deadline and Encourages Investors with Losses to Contact the Firm

Feb 10, 2025, 7:00 PM EST - 8 months ago

APLT DEADLINE: Kessler Topaz Meltzer & Check, LLP Reminds Applied Therapeutics, Inc. (APLT) Investors of Deadline and Encourages Investors with Losses to Contact the Firm

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit - APLT

Feb 10, 2025, 5:45 AM EST - 8 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of February 18, 2025 in Applied Therapeutics, Inc. Lawsuit - APLT

Applied Therapeutics, Inc. Is Being Sued For Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

Feb 2, 2025, 11:00 AM EST - 8 months ago

Applied Therapeutics, Inc. Is Being Sued For Securities Fraud And Impacted Investors Are Urged To Contact The Schall Law Firm

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

Jan 29, 2025, 10:20 AM EST - 8 months ago

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Applied Therapeutics

SaudTwits
SaudTwits Oct. 4 at 2:43 PM
$APLT I have bought at $0.94 So, what next?
2 · Reply
nevermind889
nevermind889 Oct. 4 at 12:52 PM
$APLT 5$ PT June 2026 I hope we can get there a lot sooner!
0 · Reply
nevermind889
nevermind889 Oct. 4 at 11:59 AM
$APLT Don't forget they still have partnership with ADVANZ Pharma for the commercialization of AT-007 in Europe. Should all the pieces fall in place, they could receive milestone payment of over 130M and 20% royalty payment in Europe! https://ir.appliedtherapeutics.com/news-releases/news-release-details/applied-therapeutics-announces-partnership-advanz-pharma "Advanz Pharma receives exclusive commercial rights in the European Economic Area, Switzerland, and the UK for AT-007 in Galactosemia and SORD Deficiency, with certain rights to future indications for AT-007 in Europe."
0 · Reply
nevermind889
nevermind889 Oct. 4 at 11:42 AM
$APLT My only regret is I had another 90k USD ready to deploy but I chickened out! Plus having 420,690 shares is so meme I just had to roll with it.. we always wish we bought more right?
2 · Reply
DJW009
DJW009 Oct. 3 at 10:52 PM
$APLT Closes at $1.00 on 9.28M shares. Clearly, the shorts no longer have an impact.
1 · Reply
MrStockPops
MrStockPops Oct. 3 at 8:58 PM
$APLT concerning compliance this could jump in a big way …
2 · Reply
wavw
wavw Oct. 3 at 8:06 PM
$APLT higher-highs…don’t miss this one.
0 · Reply
nevermind889
nevermind889 Oct. 3 at 8:03 PM
$APLT Start the count. 1$ close, 10 more consecutive days and we'll be in-the-money! Week of 10/14 thru 10/18 is only 11 days away!
0 · Reply
FyCkD_FuNnY
FyCkD_FuNnY Oct. 3 at 8:01 PM
$APLT eTrade shows Closed at $1.00
0 · Reply
XQuise
XQuise Oct. 3 at 8:00 PM
$APLT 🧠👈🏻
0 · Reply
Damage111
Damage111 Oct. 3 at 8:00 PM
$APLT all good though 😃
0 · Reply
Damage111
Damage111 Oct. 3 at 7:59 PM
$APLT 😑
0 · Reply
Itsnowornever
Itsnowornever Oct. 3 at 7:54 PM
$APLT Just a little more Mini short squeeze anyone.
0 · Reply
nevermind889
nevermind889 Oct. 3 at 7:49 PM
$APLT 1$ breached again, 3rd time is the charm!
0 · Reply
nevermind889
nevermind889 Oct. 3 at 7:47 PM
$APLT Glad they have more than one drug!! BUY THE RUMOR.. and uh.. BUY MORE on the NEWS! 10/14-10/18 GLTA!
1 · Reply
Itsnowornever
Itsnowornever Oct. 3 at 7:46 PM
$APLT Considering how this slumped on Monday, we’ve gotta be happy with the bounce back. Solid platform with good news to come.
1 · Reply
Itsnowornever
Itsnowornever Oct. 3 at 7:43 PM
$APLT Probably not significant in comparison but every little counts. In October 2025, results from an ongoing single-patient investigator-initiated trial evaluating govorestat for the treatment of phosphomannomutase 2-congenital disorder glycosylation (“PMM2-CDG”) will be shared at the 2025 ASHG Annual Meeting, being held from October 14-18, 2025, in Boston, Massachusetts. PMM2-CDG is an ultra-rare mutation of the PMM2 gene and the most common congenital disorder of glycosylation We all need to get to know this company as well as Camdenbeer.
2 · Reply
nevermind889
nevermind889 Oct. 3 at 7:30 PM
$APLT
1 · Reply
Tz3sports
Tz3sports Oct. 3 at 7:17 PM
$APLT Steady accumulation on this one. Volume has been slower today vs yesterday. This morning the Stubborn $1 mental resistance was broken when Volume picked up slightly. Expecting a steady hold over the weekend for this one.
0 · Reply
nevermind889
nevermind889 Oct. 3 at 6:24 PM
$APLT Been waiting all day for this to come alive.. GLTA! Let's make the last 1.5 hours worth it!
1 · Reply
DJW009
DJW009 Oct. 3 at 6:10 PM
$APLT @CAMDENBEER You are wrong You don't know this stock. You use childish memes and act like a child throwing a fit
1 · Reply
nevermind889
nevermind889 Oct. 3 at 5:57 PM
$APLT PART#3 @CAMDENBEER ...maybe they get approved, maybe they don't. We're all adults here, able to decide for ourselves if we want to be long term traders to see the company through for the months or years. Or just be a short term trader locking in profit while there is a lot of interest and activity. The volume speaks for itself. We went from 700k daily volume to hitting 5x as much of that now. We're seeing double digit millions of share traded daily. At the end of the day, it is all a speculative play. Maybe they get approved. Maybe they don't. Time will tell. Some of us might even get lucky to own part of APLT should they get bought out. That is the dream for this company and this sector. Drug approval for rare disease treatment that will cost thousands if not tens of thousands of dollar that insurance companies will pay for. And of course, having partnership like with Advanz Pharma that will pay big milestone for drug approval so they can license it in Europe! GLTA!
2 · Reply